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Summary 
•  BRCA1-associated protein-1 (BAP1) tumor 
predisposition syndrome (BAP1-TPDS) is a 
rapidly developing area of medical research 
•  Germline mutations in this multifaceted 
autosomal dominant tumor suppressor gene 
predispose families to the development of 
uveal melanoma (UM), mesothelioma (MMe), 
cutaneous melanoma (CM), renal cell 
carcinoma (RCC), and possibly other cancers 
•  The molecular function of the gene as well as 
the clinical phenotype of the syndrome are still 
being clarified  
•  We sought to conduct a complete review of all 
published research into BAP1-TPDS to more 
thoroughly understand the clinical implications 
of BAP1 mutations 
•  This information, in conjunction with 
phenotypic characteristics such as age of 
onset, disease aggressiveness and survival, 
can aid in the management, diagnoses, 
prognoses, and therapy of these patients and 
their families 
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•  A literature review was conducted on all peer-
reviewed published articles on BAP1 and its 
drosophila homolog, Calypso 
•  A search on PubMed was directed with the 
keywords “BRCA1 associated protein-1,” 
“BAP1,” and “Calypso” 
•  77 articles pertaining to the human BAP1 
gene and its association with cancer were 
obtained. Of these, 24 articles described 
patients with germline BAP1 mutations 
•  The articles were collated and data were 
extracted via an article-by-article systematic 
review 
•  Evidence was reviewed on: 
•  Cancer types observed 
•  Clinical features of cancers 
•  Evidence supporting role of BAP1 in tumor 
suppression 
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Risk Management Recommendation 
UM Yearly ophthalmic screenings starting 
age 11. Nevi monitored biannually 
CM Yearly full body dermatological 
examinations starting age 20. Nevi 
monitored biannually 
RCC Yearly ultrasound scans and MRI every 
2 years starting age 31. 
•  BAP1 testing is appropriate for patients with 
personal/family history of 2 or more UM, CM, 
MMe, or RCC (excluding family history of only 
multiple CM) in 1st or 2nd degree relatives 
•  Test 1st degree relatives for familial mutation 
Phenotypic Characteristics of BAP1 mutation 
Possible highly penetrant gene 
Early age of onset 
Tumors are more aggressive (except MMe) 
Patients with MMe have lengthened survival 
Histologically distinct tumors 
Characteristic atypical Spitz tumors present 
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Figure 2: Germline and somatic data demonstrating BAP1 involvement 
in cancer 
Figure 1: A. Germline BAP1 mutation patients diagnosed with cancer 
B. Cancers reported in families with germline BAP1 mutations 
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•  A total of 167 individuals from 51 families 
carrying 48 BAP1 mutations have been reported 
via blood and tumor DNA sequencing, and 
obligate carriers 
•  Researchers focusing only on particular cancers 
have pursued BAP1 testing, creating an 
ascertainment bias 
•  UM, MMe, CM, and RCC are major phenotypes 
•  Certain other cancers are also more commonly 
seen in patients with germline BAP1 mutations 
(see figure 2) 
•  Cancers onset earlier in life 
•  Atypical Spitz tumors are also associated 
•  Tumors exhibit loss-of-heterozygosity 
•  Somatic mutations in sporadic tumors indicate 
BAP1 involvement in tumor development 
Figure 3: Proposed mechanism of action for histone deacetylase 
inhibitor therapies directed at BAP1 tumors 
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BAP1 mutations 
in MMe Potential histone deacetylase inhibitor 
therapies include valproic acid (VPA), 
trichostatin A (TSA), LBH-589 and Vorinostat 
(currently in Phase 2 trials for metastatic UM)  
•  Somatic BAP1 mutations are characteristic of 
higher stage, more aggressive UM and RCC 
tumors 
•  Survival in RCC patients with somatic BAP1 
mutations is significantly decreased 
•  Somatic BAP1 mutations characterize 
histologically distinct subset of UM, MMe, and 
RCC 
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Tumor Type Frequency 
in germline 
BAP1 
patients 
Frequency 
in general 
population 
SEER 
Median age of 
onset in 
germline BAP1 
carriers (range) 
Median age of 
onset in general 
population 
SEER 
Biallelic 
inactivation 
shown in 
tumor, n 
Report of somatic alteration 
in sporadic cancer 
Tumor DNA 
Sequencing 
COSMIC Point 
Mutations 
Uveal Melanoma 49/167 (29%) 0.001% 51 (16-72) 62 Yes, 7 153/725 75/198 
Mesothelioma 39/167 (23%) 0.13% 56 (34-85) 74 Yes, 7 162/406  81/260 
Cutaneous Melanoma 23/167 (14%) 3.25% 46 (25-72) 58 Yes, 4 3/60  34/904 
Renal Cell Carcinoma 17/167 (10%) 1.60% 47 (36-72) 64 Yes, 5 249/2483 117/1673 
Breast Cancer 9/93 (10%) 14.90% 58 (37-85) 61 Yes, 2 0/45  11/1653 
Basal Cell Carcinoma 11/167 (7%) - 50 (42-65) - Yes, 3   
Lung Cancer 6/167 (4%) 6.99% 56 (46-59) 70 Yes, 1 2/77 13/1741 
Cholangiocarcinoma 4/167 (2%) 0.89% 66 (47-71) 50 N/A 44/502  12/1154 
Meningioma 2/167 (1%) - 52 65 Yes, 1   
